Zoetis slumps after trimming full-year forecast, Q1 miss
07/05/2026 15:11
Updates ** Shares of Zoetis ZTS.N fall 20.1% to $88.83 in morning trading ** The animal healthcare company cuts annual EPS forecast to $6.85-$7.00 from $7.00-$7.10 ** Reports Q1 adjusted EPS of $1.53, below analysts' average estimate of $1.61 – per LSEG data ** Posts Q1 revenue of $2.26 billion vs analysts' estimate of $2.31 billion ** Leerink Partners analyst Daniel Clark says U.S. companion-animal sales missed expectations due to competition, price sensitivity ** As of last close, stock down ~12% (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies